Home / Market News / $RFL

$RFL news and market catalysts

The 5 most recent market catalysts affecting $RFL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

5 catalysts 3 high impact 2 bullish 3 bearish Biotechnology
Oct 30, 2026 Corporate Catalyst Bearish Impact 65
Rafael Holdings Reports Fiscal 2026 Financial Results
Rafael Holdings (RFL) reported a net loss of $29.6 million for fiscal year 2026, a marginal improvement from the previous year. While the Q4 loss narrowed due to reduced G&A expens…
Oct 29, 2026 Corporate Catalyst Bullish Impact 85
Rafael Holdings Subsidiary Submits NDA for Trappsol® Cyclo™
Rafael Holdings announced that its subsidiary, Cyclo Therapeutics, has submitted a New Drug Application (NDA) to the FDA for remibetadex (Trappsol® Cyclo™) for Niemann-Pick Disease…
Sep 30, 2026 Corporate Catalyst Bearish Impact 95
Why Is Rafael Stock Falling Wednesday?
Rafael Holdings Inc. (RFL) experienced a sharp decline in its stock price due to the announcement that its key Phase 3 clinical trial for Trappsol Cyclo, targeting Niemann-Pick Dis…
Sep 30, 2026 Corporate Catalyst Bearish Impact 95
Rafael Holdings shares are trading lower after its subsidiary reported that Trappsol Cyclo missed the primary endpoint in a pivotal Phase 3 study.
The failure of Trappsol Cyclo in a pivotal Phase 3 study is a catastrophic event for Rafael Holdings. Pivotal Phase 3 trials are the final stage before seeking regulatory approval,…
Sep 30, 2026 Corporate Catalyst Bullish Impact 75
Rafael Holdings Announced Topline Efficacy And Safety Data From Its Cyclo Therapeutics Subsidiary’s Phase 3 TransportNPC Study Evaluating Trappsol Cyclo In 94 Patients Diagnosed With Niemann-Pick Disease Type C; Trappsol Cyclo Did Not Achieve Statistical Significance
Rafael Holdings' Cyclo Therapeutics subsidiary reported mixed results for its Phase 3 Trappsol Cyclo study. While the primary endpoint for the overall patient population was not me…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.